Splenomegaly in FOLFOX-naive stage IV or recurrent colorectal cancer patients due to chemotherapy-associated hepatotoxicity can be predicted by the aspartate aminotransferase to platelet ratio before chemotherapy
Background Chemotherapy-associated hepatotoxicity is a common cause of postoperative complications after major hepatectomy. Splenomegaly may indicate portal hypertension due to chemotherapy. To identify chemotherapy-naïve patients with liver damage, the splenic volume (SV) and aspartate aminotransfe...
Saved in:
| Published in: | International journal of clinical oncology Vol. 16; no. 3; pp. 257 - 263 |
|---|---|
| Main Authors: | , , , , , , , , , , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
Japan
Springer Japan
01.06.2011
Springer Nature B.V |
| Subjects: | |
| ISSN: | 1341-9625, 1437-7772, 1437-7772 |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | Background
Chemotherapy-associated hepatotoxicity is a common cause of postoperative complications after major hepatectomy. Splenomegaly may indicate portal hypertension due to chemotherapy. To identify chemotherapy-naïve patients with liver damage, the splenic volume (SV) and aspartate aminotransferase to platelet ratio (APR) were investigated.
Methods
Seventy-one patients receiving FOLFIRI, FOLFOX, or FOLFOX plus bevacizumab as first-line chemotherapy were included in this study. The SV measurement was performed by helical computed tomography volumetry, and the SV index (SVI) was calculated during 6 cycles of chemotherapy. The APR was used as an indicator of liver injury and the APR index (APRI) was calculated.
Results
The SVI and APRI were significantly higher in the FOLFOX group than in the FOLFIRI group. In the FOLFOX group, the maximum APR during FOLFOX administration was significantly higher in the subjects with SVI ≥ +30% than in those with SVI < +30% (
p
< 0.01). The incidences of grade 3 or 4 adverse events and grade 2 or greater histopathological sinusoidal injury were significantly higher in the SVI ≥ +30% than in the SVI < +30% group. Interestingly, the SVI was significantly higher in the group with APR ≥ 0.17 before FOLFOX than in the subjects with an APR < 0.17 before FOLFOX (
p
< 0.05).
Conclusion
Splenomegaly due to FOLFOX-associated hepatotoxicity can be predicted if the APR before FOLFOX is 0.17 or higher. |
|---|---|
| AbstractList | Chemotherapy-associated hepatotoxicity is a common cause of postoperative complications after major hepatectomy. Splenomegaly may indicate portal hypertension due to chemotherapy. To identify chemotherapy-naïve patients with liver damage, the splenic volume (SV) and aspartate aminotransferase to platelet ratio (APR) were investigated.BACKGROUNDChemotherapy-associated hepatotoxicity is a common cause of postoperative complications after major hepatectomy. Splenomegaly may indicate portal hypertension due to chemotherapy. To identify chemotherapy-naïve patients with liver damage, the splenic volume (SV) and aspartate aminotransferase to platelet ratio (APR) were investigated.Seventy-one patients receiving FOLFIRI, FOLFOX, or FOLFOX plus bevacizumab as first-line chemotherapy were included in this study. The SV measurement was performed by helical computed tomography volumetry, and the SV index (SVI) was calculated during 6 cycles of chemotherapy. The APR was used as an indicator of liver injury and the APR index (APRI) was calculated.METHODSSeventy-one patients receiving FOLFIRI, FOLFOX, or FOLFOX plus bevacizumab as first-line chemotherapy were included in this study. The SV measurement was performed by helical computed tomography volumetry, and the SV index (SVI) was calculated during 6 cycles of chemotherapy. The APR was used as an indicator of liver injury and the APR index (APRI) was calculated.The SVI and APRI were significantly higher in the FOLFOX group than in the FOLFIRI group. In the FOLFOX group, the maximum APR during FOLFOX administration was significantly higher in the subjects with SVI ≥ +30% than in those with SVI < +30% (p < 0.01). The incidences of grade 3 or 4 adverse events and grade 2 or greater histopathological sinusoidal injury were significantly higher in the SVI ≥ +30% than in the SVI < +30% group. Interestingly, the SVI was significantly higher in the group with APR ≥ 0.17 before FOLFOX than in the subjects with an APR < 0.17 before FOLFOX (p < 0.05).RESULTSThe SVI and APRI were significantly higher in the FOLFOX group than in the FOLFIRI group. In the FOLFOX group, the maximum APR during FOLFOX administration was significantly higher in the subjects with SVI ≥ +30% than in those with SVI < +30% (p < 0.01). The incidences of grade 3 or 4 adverse events and grade 2 or greater histopathological sinusoidal injury were significantly higher in the SVI ≥ +30% than in the SVI < +30% group. Interestingly, the SVI was significantly higher in the group with APR ≥ 0.17 before FOLFOX than in the subjects with an APR < 0.17 before FOLFOX (p < 0.05).Splenomegaly due to FOLFOX-associated hepatotoxicity can be predicted if the APR before FOLFOX is 0.17 or higher.CONCLUSIONSplenomegaly due to FOLFOX-associated hepatotoxicity can be predicted if the APR before FOLFOX is 0.17 or higher. Background Chemotherapy-associated hepatotoxicity is a common cause of postoperative complications after major hepatectomy. Splenomegaly may indicate portal hypertension due to chemotherapy. To identify chemotherapy-naïve patients with liver damage, the splenic volume (SV) and aspartate aminotransferase to platelet ratio (APR) were investigated. Methods Seventy-one patients receiving FOLFIRI, FOLFOX, or FOLFOX plus bevacizumab as first-line chemotherapy were included in this study. The SV measurement was performed by helical computed tomography volumetry, and the SV index (SVI) was calculated during 6 cycles of chemotherapy. The APR was used as an indicator of liver injury and the APR index (APRI) was calculated. Results The SVI and APRI were significantly higher in the FOLFOX group than in the FOLFIRI group. In the FOLFOX group, the maximum APR during FOLFOX administration was significantly higher in the subjects with SVI ≥ +30% than in those with SVI < +30% ( p < 0.01). The incidences of grade 3 or 4 adverse events and grade 2 or greater histopathological sinusoidal injury were significantly higher in the SVI ≥ +30% than in the SVI < +30% group. Interestingly, the SVI was significantly higher in the group with APR ≥ 0.17 before FOLFOX than in the subjects with an APR < 0.17 before FOLFOX ( p < 0.05). Conclusion Splenomegaly due to FOLFOX-associated hepatotoxicity can be predicted if the APR before FOLFOX is 0.17 or higher. Chemotherapy-associated hepatotoxicity is a common cause of postoperative complications after major hepatectomy. Splenomegaly may indicate portal hypertension due to chemotherapy. To identify chemotherapy-naïve patients with liver damage, the splenic volume (SV) and aspartate aminotransferase to platelet ratio (APR) were investigated. Seventy-one patients receiving FOLFIRI, FOLFOX, or FOLFOX plus bevacizumab as first-line chemotherapy were included in this study. The SV measurement was performed by helical computed tomography volumetry, and the SV index (SVI) was calculated during 6 cycles of chemotherapy. The APR was used as an indicator of liver injury and the APR index (APRI) was calculated. The SVI and APRI were significantly higher in the FOLFOX group than in the FOLFIRI group. In the FOLFOX group, the maximum APR during FOLFOX administration was significantly higher in the subjects with SVI ≥ +30% than in those with SVI < +30% (p < 0.01). The incidences of grade 3 or 4 adverse events and grade 2 or greater histopathological sinusoidal injury were significantly higher in the SVI ≥ +30% than in the SVI < +30% group. Interestingly, the SVI was significantly higher in the group with APR ≥ 0.17 before FOLFOX than in the subjects with an APR < 0.17 before FOLFOX (p < 0.05). Splenomegaly due to FOLFOX-associated hepatotoxicity can be predicted if the APR before FOLFOX is 0.17 or higher. Chemotherapy-associated hepatotoxicity is a common cause of postoperative complications after major hepatectomy. Splenomegaly may indicate portal hypertension due to chemotherapy. To identify chemotherapy-naïve patients with liver damage, the splenic volume (SV) and aspartate aminotransferase to platelet ratio (APR) were investigated. Seventy-one patients receiving FOLFIRI, FOLFOX, or FOLFOX plus bevacizumab as first-line chemotherapy were included in this study. The SV measurement was performed by helical computed tomography volumetry, and the SV index (SVI) was calculated during 6 cycles of chemotherapy. The APR was used as an indicator of liver injury and the APR index (APRI) was calculated. The SVI and APRI were significantly higher in the FOLFOX group than in the FOLFIRI group. In the FOLFOX group, the maximum APR during FOLFOX administration was significantly higher in the subjects with SVI ≥ +30% than in those with SVI < +30% (p < 0.01). The incidences of grade 3 or 4 adverse events and grade 2 or greater histopathological sinusoidal injury were significantly higher in the SVI ≥ +30% than in the SVI < +30% group. Interestingly, the SVI was significantly higher in the group with APR ≥ 0.17 before FOLFOX than in the subjects with an APR < 0.17 before FOLFOX (p < 0.05). Splenomegaly due to FOLFOX-associated hepatotoxicity can be predicted if the APR before FOLFOX is 0.17 or higher.[PUBLICATION ABSTRACT] |
| Author | ARAI Tatsuhiro MAKIZUMI Ryoji NAKANO Hiroshi SHIMAMURA Tsukasa KOBAYASHI Shinjiro SAKURAI Joe KOIKE Junki MIYAJIMA Nobuyoshi OTSUBO Takehito KOIZUMI Satoshi YAMADA Kyoji MIURA Kazuhiro |
| Author_xml | – sequence: 1 givenname: Kazuhiro surname: Miura fullname: Miura, Kazuhiro organization: Department of Gastroenterological Surgery, St. Marianna University Hospital, St. Marianna University School of Medicine – sequence: 2 givenname: Hiroshi surname: Nakano fullname: Nakano, Hiroshi email: nakahiro@marianna-u.ac.jp organization: Department of Gastroenterological Surgery, St. Marianna University Hospital, St. Marianna University School of Medicine – sequence: 3 givenname: Joe surname: Sakurai fullname: Sakurai, Joe organization: Department of Gastroenterological Surgery, St. Marianna University Hospital, St. Marianna University School of Medicine – sequence: 4 givenname: Shinjiro surname: Kobayashi fullname: Kobayashi, Shinjiro organization: Department of Gastroenterological Surgery, St. Marianna University Hospital, St. Marianna University School of Medicine – sequence: 5 givenname: Satoshi surname: Koizumi fullname: Koizumi, Satoshi organization: Department of Gastroenterological Surgery, St. Marianna University Hospital, St. Marianna University School of Medicine – sequence: 6 givenname: Tatsuhiro surname: Arai fullname: Arai, Tatsuhiro organization: Department of Gastroenterological Surgery, St. Marianna University Hospital, St. Marianna University School of Medicine – sequence: 7 givenname: Tsukasa surname: Shimamura fullname: Shimamura, Tsukasa organization: Department of Gastroenterological Surgery, St. Marianna University Hospital, St. Marianna University School of Medicine – sequence: 8 givenname: Ryoji surname: Makizumi fullname: Makizumi, Ryoji organization: Department of Gastroenterological Surgery, St. Marianna University Hospital, St. Marianna University School of Medicine – sequence: 9 givenname: Kyoji surname: Yamada fullname: Yamada, Kyoji organization: Department of Surgery, Kawasaki City Tama Hospital – sequence: 10 givenname: Nobuyoshi surname: Miyajima fullname: Miyajima, Nobuyoshi organization: Center of Gastroenterology, St. Marianna Toyoko Hospital – sequence: 11 givenname: Takehito surname: Otsubo fullname: Otsubo, Takehito organization: Department of Gastroenterological Surgery, St. Marianna University Hospital, St. Marianna University School of Medicine – sequence: 12 givenname: Junki surname: Koike fullname: Koike, Junki organization: Department of Diagnostic Pathology, St. Marianna University School of Medicine |
| BackLink | https://cir.nii.ac.jp/crid/1572543024919853952$$DView record in CiNii https://www.ncbi.nlm.nih.gov/pubmed/21243394$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kktv1DAQxyNURB_wAbggCyFxCvgZJ0dUsaXSSnvgIW7RxDvZdZXYwXYq9nvygeqwrRA99OCX5vf_z2g858WJ8w6L4jWjHxil-mNklEldUkbz0lVJnxVnTApdaq35Sb4Lycqm4uq0OI_xhi6Q4i-KU864FKKRZ8Wfr9OAzo-4g-FArCOrzXq1-Vk6sLdIYoIdkusfxAcS0MwhoEvE-MHnV4KBGHAGA5kg2RyJZDsjSZ6YPY4-7THAdCghRm8sJNySPWbSJ__bGpsOi5p0SKaAW2uWeHcgWUUgThBSVhAYrfMpgIt9Not_zachRwZMJOSsPhv0uZr_Ur4snvcwRHx1f14U31efv11-Kdebq-vLT-vSCFHTsgPgAFJVSmvR9z3UigHXslaqF9owY7iqBFdCdqxjtDGN6Gq5ZWCk4VhRcVG8P_pOwf-aMaZ2tNHgMIBDP8e21rnNNW8W8u0j8sbPweXiFojVsqpYht7cQ3M34radgh0hHNqH38qAPgIm-BgD9m1u49IEl1tkh5bRdpmL9jgXbZ6LdvnydsnPHikfzJ_S8KMmZtbtMPyr-SnRu6PIWZurW3amNFdSUC4b1tRKNIqLO3Cr2D4 |
| CitedBy_id | crossref_primary_10_3892_mco_2015_512 crossref_primary_10_1007_s12328_012_0333_2 crossref_primary_10_1002_adtp_201800154 crossref_primary_10_1007_s00261_012_9899_x crossref_primary_10_1097_MD_0000000000002454 crossref_primary_10_1016_j_jhep_2015_07_040 crossref_primary_10_22416_1382_4376_2025_35_3_94_103 crossref_primary_10_1007_s12328_017_0814_4 crossref_primary_10_1111_hepr_12107 crossref_primary_10_1007_s10147_022_02235_4 crossref_primary_10_1016_j_jhep_2017_01_031 crossref_primary_10_1002_ags3_12580 crossref_primary_10_1111_j_1477_2574_2012_00540_x crossref_primary_10_3892_mmr_2017_6407 crossref_primary_10_1007_s12328_018_0873_1 crossref_primary_10_1016_j_suronc_2016_05_030 crossref_primary_10_1080_1120009X_2023_2246786 |
| Cites_doi | 10.1016/j.jamcollsurg.2005.01.024 10.1200/JCO.2008.17.5299 10.1200/JCO.2006.09.6305 10.1097/SLA.0b013e31815774de 10.1200/JCO.2007.11.6566 10.1007/s12029-009-9063-1 10.1200/JCO.2006.05.8156 10.1245/s10434-009-0447-z 10.1016/j.jamcollsurg.2007.06.290 10.1097/00004728-200009000-00022 10.1200/JCO.2005.05.3074 10.1200/JCO.2009.27.5701 10.1093/annonc/mdi193 10.1097/01.sla.0000145964.08365.01 10.1111/j.1478-3231.2006.01356.x 10.1200/JCO.2008.17.7857 10.1097/01.sla.0000251747.80025.b7 10.1200/JCO.2008.16.1893 10.2169/internalmedicine.47.0595 10.1016/S1470-2045(09)70064-6 10.1056/NEJMoa032691 10.1002/bjs.5719 10.1016/S0140-6736(08)60455-9 10.1159/000210025 10.1093/annonc/mdn557 10.1093/annonc/mdh095 10.1016/j.ejso.2008.12.013 10.1200/JCO.2000.18.16.2938 10.1200/jco.2009.27.15_suppl.4097 |
| ContentType | Journal Article |
| Copyright | Japan Society of Clinical Oncology 2011 |
| Copyright_xml | – notice: Japan Society of Clinical Oncology 2011 |
| DBID | RYH AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7TO 7X7 7XB 88E 8AO 8C1 8FI 8FJ 8FK 8G5 ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH GNUQQ GUQSH H94 K9. M0S M1P M2O MBDVC PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS Q9U 7X8 |
| DOI | 10.1007/s10147-010-0176-0 |
| DatabaseName | CiNii Complete CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Oncogenes and Growth Factors Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Pharma Collection Public Health Database Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) Research Library (Alumni Edition) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials AUTh Library subscriptions: ProQuest Central ProQuest One Community College ProQuest Central Korea Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student Research Library Prep AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Health & Medical Collection (Alumni Edition) Medical Database Research Library Research Library (Corporate) ProQuest Central Premium ProQuest One Academic ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China ProQuest Central Basic MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Research Library Prep ProQuest Central Student Oncogenes and Growth Factors Abstracts ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing Research Library (Alumni Edition) ProQuest Pharma Collection ProQuest Central China ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Health & Medical Research Collection AIDS and Cancer Research Abstracts ProQuest Research Library ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Public Health ProQuest Central Basic ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE Research Library Prep |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1437-7772 |
| EndPage | 263 |
| ExternalDocumentID | 2377213941 21243394 10_1007_s10147_010_0176_0 10029527086 |
| Genre | Journal Article |
| GroupedDBID | --- -~C .55 .86 .VR 06C 06D 0R~ 0VY 1N0 1SB 203 29J 29~ 2J2 2JN 2JY 2KG 2LR 2VQ 2~H 30V 36B 4.4 406 408 409 40D 40E 53G 5GY 5VS 67Z 6NX 7X7 88E 8AO 8C1 8FI 8FJ 8G5 8TC 8UJ 95- 95. 95~ 96X AABHQ AACDK AAHNG AAIAL AAJBT AAJKR AANXM AANZL AAPKM AARHV AARTL AASML AATNV AATVU AAUYE AAWCG AAYIU AAYQN AAYTO AAYZH ABAKF ABBBX ABBRH ABBXA ABDBE ABDZT ABECU ABFSG ABFTV ABHLI ABHQN ABIPD ABJNI ABJOX ABKCH ABKTR ABMNI ABMQK ABNWP ABPLI ABQBU ABQSL ABSXP ABTEG ABTKH ABTMW ABULA ABUWG ABWNU ABXPI ACAOD ACDTI ACGFS ACHSB ACHXU ACKNC ACMDZ ACMLO ACOKC ACOMO ACPIV ACPRK ACSNA ACSTC ACZOJ ADBBV ADHHG ADHIR ADHKG ADJJI ADKNI ADKPE ADRFC ADTPH ADURQ ADYFF ADZKW AEBTG AEFQL AEGAL AEGNC AEJHL AEJRE AEKMD AEMSY AENEX AEOHA AEPYU AESKC AETLH AEVLU AEXYK AEZWR AFBBN AFDZB AFHIU AFKRA AFLOW AFQWF AFWTZ AFZKB AGAYW AGDGC AGJBK AGMZJ AGQEE AGQMX AGQPQ AGRTI AGWIL AGWZB AGYKE AHBYD AHIZS AHMBA AHPBZ AHSBF AHWEU AHYZX AIAKS AIGIU AIIXL AILAN AITGF AIXLP AJBLW AJRNO AJZVZ AKMHD ALIPV ALMA_UNASSIGNED_HOLDINGS ALWAN AMKLP AMXSW AMYLF AMYQR AOCGG ARMRJ ASPBG ATHPR AVWKF AXYYD AYFIA AZFZN AZQEC B-. BA0 BDATZ BENPR BGNMA BPHCQ BSONS BVXVI CAG CCPQU COF CS3 CSCUP DDRTE DL5 DNIVK DPUIP DU5 DWQXO EBLON EBS EIOEI EJD EMB EMOBN EN4 ESBYG FEDTE FERAY FFXSO FIGPU FINBP FNLPD FRRFC FSGXE FWDCC FYUFA G-Y G-Z GGCAI GGRSB GJIRD GNUQQ GNWQR GQ7 GQ8 GUQSH GXS HF~ HG5 HG6 HMCUK HMJXF HQYDN HRMNR HVGLF HZ~ I09 IJ- IKXTQ IMOTQ IWAJR IXC IXD IXE IZIGR IZQ I~X I~Z J-C J0Z JBSCW JCJTX JZLTJ KDC KOV KPH LAS LLZTM M1P M2O M4Y MA- N2Q N9A NB0 NPVJJ NQJWS NU0 O9- O93 O9G O9I O9J OAM P19 P2P P9S PF0 PHGZM PHGZT PQQKQ PROAC PSQYO PT4 PT5 Q2X QOK QOR QOS R89 R9I RHV ROL RPX RRX RSV RYH S16 S27 S37 S3B SAP SDH SDM SHX SISQX SJYHP SMD SNE SNPRN SNX SOHCF SOJ SPISZ SRMVM SSLCW SSXJD STPWE SV3 SZ9 SZN T13 TSG TSK TSV TT1 TUC U2A U9L UG4 UKHRP UOJIU UTJUX UZXMN VC2 VFIZW W23 W48 WJK WK8 X7M YLTOR Z45 ZMTXR ZOVNA ~A9 ~EX -53 -5E -5G -BR -EM -Y2 2.D 28- 2P1 3V. 5QI AAAVM ACUDM ADINQ AEFIE AFEXP AGGDS AHAVH BBWZM EBD GQ6 GRRUI H13 IHE KOW NDZJH R4E RNI RZK S1Z S26 S28 SCLPG SDE T16 Z7U Z82 Z83 Z87 Z8O Z8V Z91 AAYXX ABRTQ AFFHD AFOHR CITATION PJZUB PPXIY CGR CUY CVF ECM EIF NPM 7TO 7XB 8FK H94 K9. MBDVC PKEHL PQEST PQUKI PRINS Q9U 7X8 |
| ID | FETCH-LOGICAL-c3380-baa2aa4565773fffa851a274855f37c1cc25632534b1b109c93b84d1ac4c2e603 |
| IEDL.DBID | RSV |
| ISSN | 1341-9625 1437-7772 |
| IngestDate | Sun Nov 09 11:04:14 EST 2025 Tue Nov 04 17:03:54 EST 2025 Mon Jul 21 05:46:31 EDT 2025 Sat Nov 29 03:51:19 EST 2025 Tue Nov 18 22:24:15 EST 2025 Fri Feb 21 02:33:39 EST 2025 Thu Jun 26 22:52:08 EDT 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 3 |
| Keywords | Aspartate aminotransferase to platelet ratio index Splenomegaly Chemotherapy-naïve patients Splenic volume index Chemotherapy-associated hepatotoxicity |
| Language | English |
| License | http://www.springer.com/tdm |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c3380-baa2aa4565773fffa851a274855f37c1cc25632534b1b109c93b84d1ac4c2e603 |
| Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 14 ObjectType-Article-1 ObjectType-Feature-2 content type line 23 |
| PMID | 21243394 |
| PQID | 872184661 |
| PQPubID | 43390 |
| PageCount | 7 |
| ParticipantIDs | proquest_miscellaneous_872438290 proquest_journals_872184661 pubmed_primary_21243394 crossref_citationtrail_10_1007_s10147_010_0176_0 crossref_primary_10_1007_s10147_010_0176_0 springer_journals_10_1007_s10147_010_0176_0 nii_cinii_1572543024919853952 |
| PublicationCentury | 2000 |
| PublicationDate | 2011-06-01 20110600 2011-6-00 2011-Jun 20110601 |
| PublicationDateYYYYMMDD | 2011-06-01 |
| PublicationDate_xml | – month: 06 year: 2011 text: 2011-06-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | Japan |
| PublicationPlace_xml | – name: Japan – name: Tokyo |
| PublicationTitle | International journal of clinical oncology |
| PublicationTitleAbbrev | Int J Clin Oncol |
| PublicationTitleAlternate | Int J Clin Oncol |
| PublicationYear | 2011 |
| Publisher | Springer Japan Springer Nature B.V |
| Publisher_xml | – name: Springer Japan – name: Springer Nature B.V |
| References | Giantonio, Catalano, Meropol (CR4) 2007; 25 Oki, Kakeji, Taketomi (CR23) 2008; 39 Adam, Delvart, Pascal (CR7) 2004; 240 Overman, Maru, Charnsangavej (CR25) 2010; 28 Reddy, Morse, Hurwitz (CR27) 2008; 206 Van Buren, Yang, Dallas (CR29) 2008; 26 Angitapalli, Litwin, Kumar (CR24) 2009; 76 Aranda, Valladares, Martinez-Villacampa (CR2) 2009; 20 Wicherts, Haas, Sebagh (CR19) 2009; 27 Hurwitz, Fehrenbacher, Novotny (CR5) 2004; 350 Rubbia-Brandt, Audard, Sartoretti (CR10) 2004; 15 Lin, Chang, Yang (CR16) 2008; 47 Klinger, Eipeldauer, Hacker (CR28) 2009; 35 Ward, Guthrie, Sheridan (CR22) 2008; 26 Vauthey, Pawlik, Ribero (CR11) 2006; 24 Blazer, Kishi, Maru (CR8) 2008; 26 Chun, Laurent, Maru (CR20) 2009; 10 Aloia, Sebagh, Plasse (CR12) 2006; 24 Kalofonos, Aravantinos, Kosmidis (CR3) 2005; 16 Parise, Oliveira, Figueiredo-Mendes (CR15) 2006; 26 Fernandez, Ritter, Goodwin (CR9) 2005; 200 McCormack, Petrowsky, Jochum (CR18) 2007; 245 CR21 Kesmodel, Ellis, Lin (CR26) 2008; 26 Nakano, Oussoultzoglou, Rosso (CR13) 2008; 247 Zorzi, Laurent, Pawlik (CR17) 2007; 94 Watanabe, Hosomi, Kitade (CR14) 2000; 24 de Gramont, Figer, Seymour (CR1) 2000; 18 Nordlinger, Sorbye, Glimelius (CR6) 2008; 371 Aussilhou, Dokmak, Faivre (CR30) 2009; 16 T Aloia (176_CR12) 2006; 24 BJ Giantonio (176_CR4) 2007; 25 H Nakano (176_CR13) 2008; 247 CS Lin (176_CR16) 2008; 47 DG Blazer 3rd (176_CR8) 2008; 26 SB Kesmodel (176_CR26) 2008; 26 R Adam (176_CR7) 2004; 240 L Rubbia-Brandt (176_CR10) 2004; 15 E Oki (176_CR23) 2008; 39 M Klinger (176_CR28) 2009; 35 R Angitapalli (176_CR24) 2009; 76 E Aranda (176_CR2) 2009; 20 A Gramont de (176_CR1) 2000; 18 G Buren Van 2nd (176_CR29) 2008; 26 MJ Overman (176_CR25) 2010; 28 L McCormack (176_CR18) 2007; 245 H Hurwitz (176_CR5) 2004; 350 B Nordlinger (176_CR6) 2008; 371 ER Parise (176_CR15) 2006; 26 YS Chun (176_CR20) 2009; 10 FG Fernandez (176_CR9) 2005; 200 176_CR21 S Watanabe (176_CR14) 2000; 24 SK Reddy (176_CR27) 2008; 206 B Aussilhou (176_CR30) 2009; 16 HP Kalofonos (176_CR3) 2005; 16 176_CR19 JN Vauthey (176_CR11) 2006; 24 J Ward (176_CR22) 2008; 26 D Zorzi (176_CR17) 2007; 94 18854565 - J Clin Oncol. 2008 Nov 10;26(32):5254-60 15383792 - Ann Surg. 2004 Oct;240(4):644-57; discussion 657-8 18936472 - J Clin Oncol. 2008 Nov 20;26(33):5344-51 18156931 - Ann Surg. 2008 Jan;247(1):118-24 17032410 - Liver Int. 2006 Nov;26(9):1095-9 18398149 - J Clin Oncol. 2008 Apr 10;26(11):1836-42 11045704 - J Comput Assist Tomogr. 2000 Sep-Oct;24(5):788-94 15175435 - N Engl J Med. 2004 Jun 3;350(23 ):2335-42 20406923 - J Clin Oncol. 2010 May 20;28(15):2549-55 18718892 - Ann Oncol. 2009 Feb;20(2):251-7 18779617 - J Clin Oncol. 2008 Sep 10;26(26):4304-10 15922194 - J Am Coll Surg. 2005 Jun;200(6):845-53 18379139 - Intern Med. 2008;47(7):569-75 19261256 - Lancet Oncol. 2009 Mar;10(3):278-86 14998849 - Ann Oncol. 2004 Mar;15(3):460-6 17315288 - Br J Surg. 2007 Mar;94(3):274-86 17075116 - J Clin Oncol. 2006 Nov 1;24(31):4983-90 19363584 - Ann Surg Oncol. 2009 Jun;16(6):1553-9 15855226 - Ann Oncol. 2005 Jun;16(6):869-77 17522518 - Ann Surg. 2007 Jun;245(6):923-30 18358928 - Lancet. 2008 Mar 22;371(9617):1007-16 19321964 - Oncology. 2009;76(5):363-8 18155574 - J Am Coll Surg. 2008 Jan;206(1):96-106 16648507 - J Clin Oncol. 2006 May 1;24(13):2065-72 19377909 - J Gastrointest Cancer. 2008;39(1-4):82-5 19200687 - Eur J Surg Oncol. 2009 May;35(5):515-20 17442997 - J Clin Oncol. 2007 Apr 20;25(12):1539-44 10944126 - J Clin Oncol. 2000 Aug;18(16):2938-47 |
| References_xml | – volume: 200 start-page: 845 year: 2005 end-page: 853 ident: CR9 article-title: Effect of steatohepatitis associated with irinotecan or oxaliplatin pretreatment on resectability of hepatic colorectal metastases publication-title: J Am Coll Surg doi: 10.1016/j.jamcollsurg.2005.01.024 – volume: 26 start-page: 5344 year: 2008 end-page: 5351 ident: CR8 article-title: Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases publication-title: J Clin Oncol doi: 10.1200/JCO.2008.17.5299 – volume: 25 start-page: 1539 year: 2007 end-page: 1544 ident: CR4 article-title: Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200 publication-title: J Clin Oncol doi: 10.1200/JCO.2006.09.6305 – volume: 247 start-page: 118 year: 2008 end-page: 124 ident: CR13 article-title: Sinusoidal injury increases morbidity after major hepatectomy in patients with colorectal liver metastases receiving preoperative chemotherapy publication-title: Ann Surg doi: 10.1097/SLA.0b013e31815774de – volume: 35 start-page: 515 year: 2009 end-page: 520 ident: CR28 article-title: Bevacizumab protects against sinusoidal obstruction syndrome and does not increase response rate in neoadjuvant XELOX/FOLFOX therapy of colorectal cancer liver metastases publication-title: Eur J Surg Oncol – volume: 26 start-page: 1836 year: 2008 end-page: 1842 ident: CR29 article-title: Effect of molecular therapeutics on liver regeneration in a murine model publication-title: J Clin Oncol doi: 10.1200/JCO.2007.11.6566 – volume: 39 start-page: 82 issue: 1–4 year: 2008 end-page: 85 ident: CR23 article-title: Transient elastography for the prediction of oxaliplatin-associated liver injury in colon cancer patients: a preliminary analysis publication-title: J Gastrointest Cancer doi: 10.1007/s12029-009-9063-1 – volume: 24 start-page: 4983 year: 2006 end-page: 4990 ident: CR12 article-title: Liver histology and surgical outcomes after preoperative chemotherapy with fluorouracil plus oxaliplatin in colorectal cancer liver metastases publication-title: J Clin Oncol doi: 10.1200/JCO.2006.05.8156 – volume: 16 start-page: 1553 year: 2009 end-page: 1559 ident: CR30 article-title: Preoperative liver hypertrophy induced by portal flow occlusion before major hepatic resection for colorectal metastases can be impaired by bevacizumab publication-title: Ann Surg Oncol doi: 10.1245/s10434-009-0447-z – volume: 206 start-page: 96 year: 2008 end-page: 106 ident: CR27 article-title: Addition of bevacizumab to irinotecan- and oxaliplatin-based preoperative chemotherapy regimens does not increase morbidity after resection of colorectal liver metastases publication-title: J Am Coll Surg doi: 10.1016/j.jamcollsurg.2007.06.290 – volume: 24 start-page: 788 year: 2000 end-page: 794 ident: CR14 article-title: Assessment of the presence and severity of esophagogastric varices by splenic index in patients with liver cirrhosis publication-title: J Comput Assist Tomogr doi: 10.1097/00004728-200009000-00022 – ident: CR21 – volume: 27 start-page: suppl issue: 15s year: 2009 ident: CR19 article-title: Liver regenerative nodular hyperplasia consecutive to preoperative chemotherapy: impact on outcome of liver surgery for colorectal metastases publication-title: J Clin Oncol – volume: 24 start-page: 2065 year: 2006 end-page: 2072 ident: CR11 article-title: Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases publication-title: J Clin Oncol doi: 10.1200/JCO.2005.05.3074 – volume: 28 start-page: 2549 year: 2010 end-page: 2555 ident: CR25 article-title: Oxaliplatin-mediated increase in spleen size as a biomarker for the development of hepatic sinusoidal injury publication-title: J Clin Oncol doi: 10.1200/JCO.2009.27.5701 – volume: 16 start-page: 869 year: 2005 end-page: 877 ident: CR3 article-title: Irinotecan or oxaliplatin combined with leucovorin and 5-fluorouracil as first-line treatment in advanced colorectal cancer: a multicenter, randomized, phase II study publication-title: Ann Oncol doi: 10.1093/annonc/mdi193 – volume: 240 start-page: 644 year: 2004 end-page: 657 ident: CR7 article-title: Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival publication-title: Ann Surg doi: 10.1097/01.sla.0000145964.08365.01 – volume: 26 start-page: 1095 year: 2006 end-page: 1099 ident: CR15 article-title: Noninvasive serum markers in the diagnosis of structural liver damage in chronic hepatitis C virus infection publication-title: Liver Int doi: 10.1111/j.1478-3231.2006.01356.x – volume: 26 start-page: 5254 year: 2008 end-page: 5260 ident: CR26 article-title: Preoperative bevacizumab does not significantly increase postoperative complication rates in patients undergoing hepatic surgery for colorectal cancer liver metastases publication-title: J Clin Oncol doi: 10.1200/JCO.2008.17.7857 – volume: 245 start-page: 923 year: 2007 end-page: 930 ident: CR18 article-title: Hepatic steatosis is a risk factor for postoperative complications after major hepatectomy: a matched case–control study publication-title: Ann Surg doi: 10.1097/01.sla.0000251747.80025.b7 – volume: 26 start-page: 4304 year: 2008 end-page: 4310 ident: CR22 article-title: Sinusoidal obstructive syndrome diagnosed with superparamagnetic iron oxide-enhanced magnetic resonance imaging in patients with chemotherapy-treated colorectal liver metastases publication-title: J Clin Oncol doi: 10.1200/JCO.2008.16.1893 – volume: 47 start-page: 569 year: 2008 end-page: 575 ident: CR16 article-title: Retrospective evaluation of serum markers APRI and AST/ALT for assessing liver fibrosis and cirrhosis in chronic hepatitis B and C patients with hepatocellular carcinoma publication-title: Intern Med doi: 10.2169/internalmedicine.47.0595 – volume: 10 start-page: 278 year: 2009 end-page: 286 ident: CR20 article-title: Management of chemotherapy-associated hepatotoxicity in colorectal liver metastases publication-title: Lancet Oncol doi: 10.1016/S1470-2045(09)70064-6 – volume: 18 start-page: 2938 year: 2000 end-page: 2947 ident: CR1 article-title: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer publication-title: J Clin Oncol – volume: 350 start-page: 2335 year: 2004 end-page: 2342 ident: CR5 article-title: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer publication-title: N Engl J Med doi: 10.1056/NEJMoa032691 – volume: 94 start-page: 274 year: 2007 end-page: 286 ident: CR17 article-title: Chemotherapy-associated hepatotoxicity and surgery for colorectal liver metastases publication-title: Br J Surg doi: 10.1002/bjs.5719 – volume: 371 start-page: 1007 year: 2008 end-page: 1016 ident: CR6 article-title: Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial publication-title: Lancet doi: 10.1016/S0140-6736(08)60455-9 – volume: 76 start-page: 363 year: 2009 end-page: 368 ident: CR24 article-title: Adjuvant FOLFOX chemotherapy and splenomegaly in patients with stages II–III colorectal cancer publication-title: Oncology doi: 10.1159/000210025 – volume: 20 start-page: 251 year: 2009 end-page: 257 ident: CR2 article-title: Randomized study of weekly irinotecan plus high-dose 5-fluorouracil (FUIRI) versus biweekly irinotecan plus 5-fluorouracil/leucovorin (FOLFIRI) as first-line chemotherapy for patients with metastatic colorectal cancer: a Spanish Cooperative Group for the Treatment of Digestive Tumors Study publication-title: Ann Oncol doi: 10.1093/annonc/mdn557 – volume: 15 start-page: 460 year: 2004 end-page: 466 ident: CR10 article-title: Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer publication-title: Ann Oncol doi: 10.1093/annonc/mdh095 – volume: 47 start-page: 569 year: 2008 ident: 176_CR16 publication-title: Intern Med doi: 10.2169/internalmedicine.47.0595 – volume: 26 start-page: 5254 year: 2008 ident: 176_CR26 publication-title: J Clin Oncol doi: 10.1200/JCO.2008.17.7857 – volume: 76 start-page: 363 year: 2009 ident: 176_CR24 publication-title: Oncology doi: 10.1159/000210025 – volume: 26 start-page: 1095 year: 2006 ident: 176_CR15 publication-title: Liver Int doi: 10.1111/j.1478-3231.2006.01356.x – volume: 26 start-page: 4304 year: 2008 ident: 176_CR22 publication-title: J Clin Oncol doi: 10.1200/JCO.2008.16.1893 – volume: 245 start-page: 923 year: 2007 ident: 176_CR18 publication-title: Ann Surg doi: 10.1097/01.sla.0000251747.80025.b7 – volume: 247 start-page: 118 year: 2008 ident: 176_CR13 publication-title: Ann Surg doi: 10.1097/SLA.0b013e31815774de – volume: 26 start-page: 5344 year: 2008 ident: 176_CR8 publication-title: J Clin Oncol doi: 10.1200/JCO.2008.17.5299 – volume: 94 start-page: 274 year: 2007 ident: 176_CR17 publication-title: Br J Surg doi: 10.1002/bjs.5719 – volume: 371 start-page: 1007 year: 2008 ident: 176_CR6 publication-title: Lancet doi: 10.1016/S0140-6736(08)60455-9 – volume: 24 start-page: 2065 year: 2006 ident: 176_CR11 publication-title: J Clin Oncol doi: 10.1200/JCO.2005.05.3074 – volume: 206 start-page: 96 year: 2008 ident: 176_CR27 publication-title: J Am Coll Surg doi: 10.1016/j.jamcollsurg.2007.06.290 – volume: 25 start-page: 1539 year: 2007 ident: 176_CR4 publication-title: J Clin Oncol doi: 10.1200/JCO.2006.09.6305 – ident: 176_CR21 doi: 10.1097/SLA.0b013e31815774de – volume: 28 start-page: 2549 year: 2010 ident: 176_CR25 publication-title: J Clin Oncol doi: 10.1200/JCO.2009.27.5701 – volume: 240 start-page: 644 year: 2004 ident: 176_CR7 publication-title: Ann Surg doi: 10.1097/01.sla.0000145964.08365.01 – volume: 24 start-page: 4983 year: 2006 ident: 176_CR12 publication-title: J Clin Oncol doi: 10.1200/JCO.2006.05.8156 – volume: 39 start-page: 82 issue: 1–4 year: 2008 ident: 176_CR23 publication-title: J Gastrointest Cancer doi: 10.1007/s12029-009-9063-1 – volume: 35 start-page: 515 year: 2009 ident: 176_CR28 publication-title: Eur J Surg Oncol doi: 10.1016/j.ejso.2008.12.013 – volume: 15 start-page: 460 year: 2004 ident: 176_CR10 publication-title: Ann Oncol doi: 10.1093/annonc/mdh095 – volume: 350 start-page: 2335 year: 2004 ident: 176_CR5 publication-title: N Engl J Med doi: 10.1056/NEJMoa032691 – volume: 24 start-page: 788 year: 2000 ident: 176_CR14 publication-title: J Comput Assist Tomogr doi: 10.1097/00004728-200009000-00022 – volume: 26 start-page: 1836 year: 2008 ident: 176_CR29 publication-title: J Clin Oncol doi: 10.1200/JCO.2007.11.6566 – volume: 20 start-page: 251 year: 2009 ident: 176_CR2 publication-title: Ann Oncol doi: 10.1093/annonc/mdn557 – volume: 16 start-page: 869 year: 2005 ident: 176_CR3 publication-title: Ann Oncol doi: 10.1093/annonc/mdi193 – volume: 16 start-page: 1553 year: 2009 ident: 176_CR30 publication-title: Ann Surg Oncol doi: 10.1245/s10434-009-0447-z – volume: 10 start-page: 278 year: 2009 ident: 176_CR20 publication-title: Lancet Oncol doi: 10.1016/S1470-2045(09)70064-6 – volume: 200 start-page: 845 year: 2005 ident: 176_CR9 publication-title: J Am Coll Surg doi: 10.1016/j.jamcollsurg.2005.01.024 – volume: 18 start-page: 2938 year: 2000 ident: 176_CR1 publication-title: J Clin Oncol doi: 10.1200/JCO.2000.18.16.2938 – ident: 176_CR19 doi: 10.1200/jco.2009.27.15_suppl.4097 – reference: 19200687 - Eur J Surg Oncol. 2009 May;35(5):515-20 – reference: 15855226 - Ann Oncol. 2005 Jun;16(6):869-77 – reference: 19377909 - J Gastrointest Cancer. 2008;39(1-4):82-5 – reference: 17442997 - J Clin Oncol. 2007 Apr 20;25(12):1539-44 – reference: 17075116 - J Clin Oncol. 2006 Nov 1;24(31):4983-90 – reference: 10944126 - J Clin Oncol. 2000 Aug;18(16):2938-47 – reference: 18398149 - J Clin Oncol. 2008 Apr 10;26(11):1836-42 – reference: 18936472 - J Clin Oncol. 2008 Nov 20;26(33):5344-51 – reference: 18155574 - J Am Coll Surg. 2008 Jan;206(1):96-106 – reference: 17522518 - Ann Surg. 2007 Jun;245(6):923-30 – reference: 18358928 - Lancet. 2008 Mar 22;371(9617):1007-16 – reference: 18718892 - Ann Oncol. 2009 Feb;20(2):251-7 – reference: 11045704 - J Comput Assist Tomogr. 2000 Sep-Oct;24(5):788-94 – reference: 17032410 - Liver Int. 2006 Nov;26(9):1095-9 – reference: 16648507 - J Clin Oncol. 2006 May 1;24(13):2065-72 – reference: 18156931 - Ann Surg. 2008 Jan;247(1):118-24 – reference: 19363584 - Ann Surg Oncol. 2009 Jun;16(6):1553-9 – reference: 15175435 - N Engl J Med. 2004 Jun 3;350(23 ):2335-42 – reference: 18379139 - Intern Med. 2008;47(7):569-75 – reference: 15383792 - Ann Surg. 2004 Oct;240(4):644-57; discussion 657-8 – reference: 18854565 - J Clin Oncol. 2008 Nov 10;26(32):5254-60 – reference: 15922194 - J Am Coll Surg. 2005 Jun;200(6):845-53 – reference: 18779617 - J Clin Oncol. 2008 Sep 10;26(26):4304-10 – reference: 17315288 - Br J Surg. 2007 Mar;94(3):274-86 – reference: 14998849 - Ann Oncol. 2004 Mar;15(3):460-6 – reference: 20406923 - J Clin Oncol. 2010 May 20;28(15):2549-55 – reference: 19321964 - Oncology. 2009;76(5):363-8 – reference: 19261256 - Lancet Oncol. 2009 Mar;10(3):278-86 |
| SSID | ssj0017652 |
| Score | 2.0228415 |
| Snippet | Background
Chemotherapy-associated hepatotoxicity is a common cause of postoperative complications after major hepatectomy. Splenomegaly may indicate portal... Chemotherapy-associated hepatotoxicity is a common cause of postoperative complications after major hepatectomy. Splenomegaly may indicate portal hypertension... |
| SourceID | proquest pubmed crossref springer nii |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 257 |
| SubjectTerms | Adenocarcinoma - drug therapy Adenocarcinoma - pathology Aged Antibodies, Monoclonal - administration & dosage Antibodies, Monoclonal - adverse effects Antibodies, Monoclonal, Humanized Antineoplastic Combined Chemotherapy Protocols - administration & dosage Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Aspartate aminotransferase to platelet ratio index Aspartate Aminotransferases - metabolism Bevacizumab Camptothecin - administration & dosage Camptothecin - adverse effects Camptothecin - analogs & derivatives Cancer Research Chemical and Drug Induced Liver Injury - diagnosis Chemical and Drug Induced Liver Injury - enzymology Chemical and Drug Induced Liver Injury - etiology Chemotherapy Chemotherapy-associated hepatotoxicity Chemotherapy-naive patients Colorectal cancer Colorectal Neoplasms - drug therapy Colorectal Neoplasms - pathology Female Fluorouracil - administration & dosage Fluorouracil - adverse effects Humans Leucovorin - administration & dosage Leucovorin - adverse effects Liver cancer Male Medicine Medicine & Public Health Middle Aged Neoplasm Staging Oncology Organoplatinum Compounds - administration & dosage Organoplatinum Compounds - adverse effects Original Article Platelet Count Radiography Retrospective Studies Splenic volume index Splenomegaly Splenomegaly - blood Splenomegaly - chemically induced Splenomegaly - diagnostic imaging Splenomegaly - enzymology Surgical Oncology Toxicity |
| SummonAdditionalLinks | – databaseName: AUTh Library subscriptions: ProQuest Central dbid: BENPR link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lj9MwELbYLkJceD_CssgHTiCLOnbq5IQAbQUSdFe81FtkO84SaZuEJEX0f_KDmEmcrFbAXrhUlRxPXPXLzDce5xtCnprYhUYpwZSIFkzqSLEEaBHLtLOoDGCF0n2zCbVaxet1cuLP5rT-WOXoE3tHnVUW98hfxAqTEYgmL-vvDJtGYXHVd9DYI_soVCZnZP_10erk41RGUIu-5Q6KlrEEmP5Y1hzeneMST13iuSwFWfWFwLRXFsXfOOcf9dI-DC1v_ucPuEVueP5JXw2AuU2uuPIOufbBV9jvkl-faohD1cZB5NjRoqTL4_fL4zUrNbhFClTy1NF3X2nV0AZ36lHbiaLwNTpOsGsRRA31aq0tzbaOdhUFZGz8q147pj0iXEa_QTDsqq76CXfvdjibGkfrBpeD42ZHYRbV4PbwzAB82xRl1fVkG4y1vfH6DEYAfrQHMxgAHu4u3PIe-bI8-vzmLfOdH5iFlHnOjNah1n1JVok8zzXwQg35cxxFuVCWWwtMTYSRkIYbPk9sIkwsM66ttKFbzMV9Miur0j0kVOcCksJMS54rKXNutBWcL4AWcSMguQ3IfPzbU-tl0bE7x1l6LuiMSEkBKSkiJZ0H5Nk0pR40QS67-BCwBKbxk0cKxQdQppEnQJSSKAzIwQiX1LuPNp2wEhA6jcJzj8UcXbpq21-CNdwEbvBgwOa0FmAjUohEBuT5CNZz0_9c6KNLF3JArg-76bj_9JjMumbrDslV-6Mr2uaJf-5-A33pM6A priority: 102 providerName: ProQuest |
| Title | Splenomegaly in FOLFOX-naive stage IV or recurrent colorectal cancer patients due to chemotherapy-associated hepatotoxicity can be predicted by the aspartate aminotransferase to platelet ratio before chemotherapy |
| URI | https://cir.nii.ac.jp/crid/1572543024919853952 https://link.springer.com/article/10.1007/s10147-010-0176-0 https://www.ncbi.nlm.nih.gov/pubmed/21243394 https://www.proquest.com/docview/872184661 https://www.proquest.com/docview/872438290 |
| Volume | 16 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 1437-7772 dateEnd: 20170531 omitProxy: false ssIdentifier: ssj0017652 issn: 1341-9625 databaseCode: BENPR dateStart: 19970301 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Health & Medical Collection customDbUrl: eissn: 1437-7772 dateEnd: 20170531 omitProxy: false ssIdentifier: ssj0017652 issn: 1341-9625 databaseCode: 7X7 dateStart: 19970301 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: Public Health Database customDbUrl: eissn: 1437-7772 dateEnd: 20170531 omitProxy: false ssIdentifier: ssj0017652 issn: 1341-9625 databaseCode: 8C1 dateStart: 19970301 isFulltext: true titleUrlDefault: https://search.proquest.com/publichealth providerName: ProQuest – providerCode: PRVPQU databaseName: Research Library customDbUrl: eissn: 1437-7772 dateEnd: 20170531 omitProxy: false ssIdentifier: ssj0017652 issn: 1341-9625 databaseCode: M2O dateStart: 19970301 isFulltext: true titleUrlDefault: https://search.proquest.com/pqrl providerName: ProQuest – providerCode: PRVAVX databaseName: Springer Journals New Starts & Take-Overs Collection customDbUrl: eissn: 1437-7772 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017652 issn: 1341-9625 databaseCode: RSV dateStart: 19970101 isFulltext: true titleUrlDefault: https://link.springer.com/search?facet-content-type=%22Journal%22 providerName: Springer Nature |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3dbtMwFLbohhA3_P-EscoXXIEsxbFTJ5cwrQKJtdMGU-8i23VGpDWpknSiT8VD8Ay8D-e4ScfEQIIbK5HtY0s-9vmOj_2ZkFcmcZFRSjAl4hGTOlYsBVjE5tpZZAawQmn_2ISaTJLZLD3u7nE3_Wn3PiTpV-pfLrtxicck8SCVAjd4QHbB2iU4G09Oz7ahAzXyz-wgURlLAd33ocybRFwzRoOyKG7Cmb_FSL3pGd__r04_IPc6pEnfblTjIbnlykfkzlEXS39MfpwuweJUCwc2Yk2Lko6nH8fTGSv192-XjgJqPHf0wxmtalrjpjzSOFHkuMY1EgRb1JeadsSsDZ2vHG0rCkqw6G51rZnuBt_N6Rewe23VVl-h-XaNtalxdFljfzDfrCnUohpWODweAF-Loqxaj6tBWOOFLy8gBzSNer0FAQC53bUmn5DP48NPB-9Z98gDs-Adh8xoHWnto69K5HmuAQJqcJWTOM6FstxaAGUiioU03PAwtakwiZxzbaWN3CgUT8lOWZXuOaE6F-D_zbXkuZIy50ZbwfkIEBA3AvzYgIT9aGe2Y0DHhzgusivuZhyuDIYrw-HKwoC83lZZbug__lZ4H1QIRGPKY4U8A8jIyFPARGkcBWSvV66sWymaLFHoZANKCgjd5sIUx7iNLl218kUwXJtCA882KrntCwAPKUQqA_Km178r0X_s6It_Kr1H7m420nHr6SXZaeuV2ye37WVbNPWQDNRM-TSBNDngQ7L77nByfAJ_R9F06CfnT2SkLkg |
| linkProvider | Springer Nature |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9QwEB61BQEX3o9QCj7ABWQRx8k6OSCECquuut0iUdDeUsdxYKVuErJZYH8U_4YfxEweW1VAbz1wiSI5HlvJPDPjbwCeJqH1EqUkVzIYcF8HikfoFvFUW0PIAEYq3TSbUJNJOJ1G7zfgZ38Whsoqe53YKOq0MPSP_GWoKBhBa_K6_MqpaRQlV_sOGi1X7NvVd4zYFq9Gb_HzPvO84buj3T3eNRXgBqMxlydae1o32T4lsyzT6HJoDM3CIMikMsIYdAKkF0g_EYlwIxPJJPRToY1vPDtwJdLdhEsEZEexXri7rigRatA0-CGINB5hXNEnUduTesKnGk-qAlMYw58xg5v5bPY3D_eP7Gxj9IY3_rPXdROud941e9OKwy3YsPltuHLQ1Q_cgV8fSrSyxdyiXVyxWc6Gh-Ph4ZTnGpU-Q0f5s2WjT6yoWEV5CEKuYgTrTWYB6RoSkYp1WLQLli4tqwuGfD_vDrKtuO743absC5r6uqiLH7h6vaLZLLGsrGg7NJ6sGM5iGpU6VUTg3XyWF3UTSiCxRUO8PMERFC7WiCoSwCjDnlnyLny8kHd6D7byIrcPgOlMYsibal9kyvczkWgjhRig0ycSiaG7A27PZrHpQN-p98hJfApXTZwZI2fGxJmx68Dz9ZSyRTw57-Ed5F0kTVcRKIJWIBBKEaEbGAWeA9s9e8adclzEa950gK1HUatRqkrntlg2j1CGOsIF7reysN4L-lq-lJHvwIteOE5J_3OjD8_dyBO4und0MI7Ho8n-Nlxr8wb0p-0RbNXV0u7AZfOtni2qx43EMzi-aJn5DSP9jQo |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9NAEB61BVVceENDKcwBLqBVs147Gx8QQi0RUUtaiYdyc9frNY3U2MFxgPw0_gc_iBk_UlVAbz1wsSytd3ZlzzcPz-wMwLO477xYayW0CnrCN4EWIZlFIjHOcmUAq7Spmk3o0ag_HofHa_CzPQvDaZWtTKwEdZJb_ke-29fsjJA22U2brIjj_cHr2VfBDaQ40Np206g55MAtv5P3Nn813KdP_dzzBm8_7r0TTYMBYckz64rYGM-YKvKnVZqmhswPQ25aPwhSpa20lgwC5QXKj2Usu6ENVdz3E2msbz3X6yqiuw7XtCIm5kPqe6vsEql7VbMfLpcmQvIx2oBqfWpP-pzvyRlhmvz5CypxPZtM_mbt_hGprRTg4NZ__Opuw83G6sY3NUzuwJrL7sLm-yav4B78-jAj7ZtPHenLJU4yHBwdDo7GIjOkDJAM6C8Oh58xL7Dg-ARXtEIu983qguhahk6BTY3aOSYLh2WOhIdpc8BtKUyDA5fgKZkAZV7mP2j1csmzMXY4K3g7PB4vkWahIWHPmRJ0N51keVm5GERsXhGfndEIgQ4rCBMB8j7chSXvw6creacPYCPLM7cFaFJFrnBifJlq309lbKySskfGoIwVufQd6LYsF9mmGDz3JDmLzstYM5dGxKURc2nU7cCL1ZRZXQnlsod3iI-JNF9loLnkAhenlCGZh2HgdWC7ZdWoEZrzaMWnHcDVKEk7DmGZzOWL6hGOXIe0wMMaF6u9kA3mKxX6HXjZAuWc9D83-ujSjTyFTYJKdDgcHWzDjTqcwD_gHsNGWSzcDly338rJvHhSgR_h5Koh8xukS5XP |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Splenomegaly+in+FOLFOX-na%C3%AFve+stage+IV+or+recurrent+colorectal+cancer+patients+due+to+chemotherapy-associated+hepatotoxicity+can+be+predicted+by+the+aspartate+aminotransferase+to+platelet+ratio+before+chemotherapy&rft.jtitle=International+journal+of+clinical+oncology&rft.au=Miura%2C+Kazuhiro&rft.au=Nakano%2C+Hiroshi&rft.au=Sakurai%2C+Joe&rft.au=Kobayashi%2C+Shinjiro&rft.date=2011-06-01&rft.issn=1437-7772&rft.eissn=1437-7772&rft.volume=16&rft.issue=3&rft.spage=257&rft_id=info:doi/10.1007%2Fs10147-010-0176-0&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1341-9625&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1341-9625&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1341-9625&client=summon |